GlassScriptPhysician profile
Patrick Owens
NPI 1790028199
$26,182.87
in general payments reported to CMS, 2019-2025
30 companies · $22K in 2025
The $22K reported for 2025 was more than what 98% of Otolaryngology providers received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $867 · 2020: $282 · 2021: $713 · 2022: $992 · 2023: $549 · 2024: $1,077 · 2025: $22K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $19K · Food and Beverage: $3,144 · Consulting Fee: $1,525 · Education: $34.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $18,625.00 |
| Food and Beverage | $3,144.35 |
| Consulting Fee | $1,525.00 |
| Education | $34.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $19,237.59 | 2022-2025 | |
| Pfizer INC. | $1,936.70 | 2023-2025 | |
| Inspire Medical Systems, INC. | $1,163.93 | 2019-2025 | Inspire |
| Intersect Ent, INC. | $721.39 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $583.49 | 2019-2025 | Dupixent |
| Optinose US, INC. | $460.02 | 2019-2025 | |
| Stryker Corporation | $373.37 | 2019-2021 | |
| Glaxosmithkline, LLC. | $327.67 | 2024-2025 | Nucala |
| Medtronic, INC. | $294.73 | 2022-2025 | Pteye Parathyroid Detection System, Propel, Ligasure |
| Genzyme Corporation | $252.90 | 2019-2025 | |
| Integra Lifesciences Corporation | $145.97 | 2019-2025 | Trudi Probe, Relieva Spinplus Nav, Inspira Air |
| Merz Pharmaceuticals, LLC | $110.41 | 2024 | Xeomin |
| Aroa Biosurgery Incorporated | $83.88 | 2024 | |
| Olympus America INC. | $61.87 | 2019 | |
| Aerin Medical INC. | $56.28 | 2025 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $53.37 | 2025 | |
| Neurent Medical Limited | $38.53 | 2025 | Neuromark Radiofrequency Console, Neuromark System |
| Ethicon US, LLC | $36.00 | 2025 | Ethicon, Vistaseal, Surgiflo Hemostatic Matrix |
| Biohaven Pharmaceutical Holding Company LTD. | $31.07 | 2022 | |
| Axsome Therapeutics, INC. | $29.35 | 2025 | Symbravo |
| Astrazeneca Pharmaceuticals LP | $25.19 | 2025 | Tezspire |
| Nuvasive, INC. | $23.26 | 2021 | |
| Acclarent, INC | $21.10 | 2019 | |
| Baudax Bio INC. | $19.01 | 2021 | |
| Ars Pharmaceuticals Operations, INC. | $18.31 | 2025 | Neffy |
| Covidien LP | $17.52 | 2020 | |
| Karl Storz Endoscopy-America | $17.18 | 2019 | |
| Merck Sharp & Dohme LLC | $16.73 | 2023 | |
| Kowa Pharmaceuticals America, INC. | $14.75 | 2023 | Seglentis |
| Cochlear Americas | $11.30 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Owens listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.